Rare diseases, real opportunity: Why the UK’s next challenge...
The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Newsletters and Deep Dive digital magazine
The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.
Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?
Pharma marketers often underestimate the value of independent pharmacies.
In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs
Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.
Editor's Picks
Newsletters and Deep Dive
digital magazine